NMD Pharma A/S: Financial statements 2016
CVR: 36899069
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -6,371,806 and a net result of DKK -6,872,801. Equity in the 2016 report amounted to DKK 13,149,857. The solvency ratio was 91%. The company had 5 employees in the financial year.
- Gross Profit
- DKK -6,371,806
- Profit/Loss
- DKK -6,872,801
- Equity
- DKK 13,149,857
- Total Assets
- DKK 14,452,170
- Employees
- 5
Official annual report
Find more companies like NMD Pharma A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
As of June 2, 2016, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NMD Pharma A/S.
As of June 2, 2016, Claus Elsborg Olesen has joined the board of directors of NMD Pharma A/S.
As of June 2, 2016, Christian Ellebæk Elling has joined the board of directors of NMD Pharma A/S.
As of June 2, 2016, Stephan Christgau has joined the board of directors of NMD Pharma A/S.
As of June 2, 2016, Patrick Volkert Jozef Johannes Vink has joined the board of directors of NMD Pharma A/S.
NMD Pharma A/S has published its interim report for the period May 7, 2015 – December 31, 2015.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 18 employees (2018). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.